Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).
You may also be interested in...
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.
Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.